Top

Published in:

18-03-2024 | Biomarkers | Original Article

Autotaxin is a potential predictive marker for the development of veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation

Authors: Kazuya Takemura, Mika Nakamae, Hiroshi Okamura, Kazuki Sakatoku, Kentaro Ido, Yosuke Makuuchi, Masatomo Kuno, Teruhito Takakuwa, Asao Hirose, Mitsutaka Nishimoto, Yasuhiro Nakashima, Hideo Koh, Koji Igarashi, Hiroshi Kubota, Masayuki Hino, Hirohisa Nakamae

Published in: Annals of Hematology | Issue 5/2024

Abstract

Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a life-threatening complication after allogeneic hematopoietic cell transplantation (allo-HCT), and stratification of the high-risk group before transplantation is significant. Serum autotaxin (ATX) levels have been reported to increase in patients with liver fibrosis caused by metabolic inhibition from liver sinusoidal endothelial cells. Considering that the pathophysiology of VOD/SOS begins with liver sinusoidal endothelial cell injury, an increase in serum ATX levels may precede the onset of VOD/SOS. A retrospective study with 252 patients, including 12 patients with VOD/SOS, who had received allo-HCT was performed. The cumulative incidence of VOD/SOS was higher in the group with serum ATX levels before conditioning (baseline ATX) above the upper reference limit (high ATX group, p < 0.001), and 1-year cumulative incidences were 22.7% (95% confidence interval [95%CI], 3.1–42.4%) and 3.5% (95%CI, 1.1–5.8%), respectively. In the multivariate analysis, elevated baseline ATX was identified as an independent risk factor for VOD/SOS development and showed an additive effect on the predictive ability of known risk factors. Furthermore, the incidence of VOD/SOS-related mortality was greater in the high ATX group (16.7% vs. 1.3%; p = 0.005). Serum ATX is a potential predictive marker for the development of VOD/SOS.

Available only for authorised users

Copelan EA (2006) Hematopoietic stem-cell transplantation. N Engl J Med 354:1813–1826. https://doi.org/10.1056/nejmc061443CrossRefPubMed

McDonald GB (2010) Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. Hepatology 51:1450–1460. https://doi.org/10.1002/hep.23533CrossRefPubMed

Palomo M, Diaz-Ricart M, Carreras E (2019) Endothelial dysfunction in hematopoietic cell transplantation. Clin Hematol Int 1:45–51. https://doi.org/10.2991/chi.d.190317.001CrossRefPubMedPubMedCentral

Palomo M, Diaz-Ricart M, Carbo C et al (2009) The release of soluble factors contributing to endothelial activation and damage after hematopoietic stem cell transplantation is not limited to the Allogeneic setting and involves several pathogenic mechanisms. Biol Blood Marrow Transpl 15:537–546. https://doi.org/10.1016/j.bbmt.2009.01.013CrossRef

Cairo MS, Cooke KR, Lazarus HM, Chao N (2020) Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation. Brit J Haematol 190:822–836. https://doi.org/10.1111/bjh.16557CrossRef

Mohty M, Malard F, Abecassis M, et al (2016) Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant 51:906–912. https://doi.org/10.1038/bmt.2016.130.

Mcdonald GB, Sharma P, Matthews DE et al (1984) Venocclusive Disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 4:116–122. https://doi.org/10.1002/hep.1840040121CrossRefPubMed

Jones RJ, Lee KSK, Beschorner WE et al (1987) Venoocclusive disease of the liver following bone marrow transplantation. Transplant 44:778–783. https://doi.org/10.1097/00007890-198712000-00011

Colecchia A, Marasco G, Ravaioli F et al (2017) Usefulness of liver stiffness measurement in predicting hepatic veno-occlusive disease development in patients who undergo HSCT. Bone Marrow Transpl 52:494–497. https://doi.org/10.1038/bmt.2016.320CrossRef

10.

Nishida M, Kahata K, Hayase E et al (2018) Novel Ultrasonographic Scoring System of Sinusoidal obstruction syndrome after hematopoietic stem cell transplantation. Biol Blood Marrow Transpl 24:1896–1900. https://doi.org/10.1016/j.bbmt.2018.05.025CrossRef

11.

Yakushijin K, Atsuta Y, Doki N et al (2016) Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transpl 51:403–409. https://doi.org/10.1038/bmt.2015.283CrossRef

12.

Mohty M, Malard F, Abecassis M et al (2015) Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl 50:781–789. https://doi.org/10.1038/bmt.2015.52CrossRef

13.

Salat C, Holler E, Kolb HJ et al (1997) Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. Blood 89:2184–2188CrossRefPubMed

14.

Faioni EM, Krachmalnicoff A, Bearman SI et al (1993) Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of the liver. Blood 81:3458–3462CrossRefPubMed

15.

Tanikawa S, Mori S, Ohhashi K et al (2000) Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study. Bone Marrow Transpl 26:881–886. https://doi.org/10.1038/sj.bmt.1702624CrossRef

16.

Stracke ML, Krutzsch HC, Unsworth EJ et al (1992) Identification, purification, and Partial Sequence Analysis of Autotaxin, a Novel motility-stimulating Protein*. J Biol Chem 267:2524–2529CrossRefPubMed

17.

Tokumura A, Majima E, Kariya Y et al (2002) Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem 277:39436–39442. https://doi.org/10.1074/jbc.m205623200CrossRefPubMed

18.

Moolenaar WH (2002) Lysophospholipids in the limelight: autotaxin takes center stage. J Cell Biol 158:197–199. https://doi.org/10.1083/jcb.200206094CrossRefPubMedPubMedCentral

19.

Aikawa S, Hashimoto T, Kano K, Aoki J (2015) Lysophosphatidic acid as a lipid mediator with multiple biological actions. J Biochem 157:81–89. https://doi.org/10.1093/jb/mvu077CrossRefPubMed

20.

Nakamura K, Ohkawa R, Okubo S et al (2007) Measurement of lysophospholipase D/autotaxin activity in human serum samples. Clin Biochem 40:274–277. https://doi.org/10.1016/j.clinbiochem.2006.10.009CrossRefPubMed

21.

Nakamura K, Igarashi K, Ide K et al (2008) Validation of an autotaxin enzyme immunoassay in human serum samples and its application to hypoalbuminemia differentiation. Clin Chim Acta 388:51–58. https://doi.org/10.1016/j.cca.2007.10.005CrossRefPubMed

22.

Yamazaki T, Joshita S, Umemura T et al (2017) Association of Serum Autotaxin Levels with liver fibrosis in patients with chronic Hepatitis C. Sci Rep 7:46705. https://doi.org/10.1038/srep46705CrossRefPubMedPubMedCentral

23.

Takemura K, Takizawa E, Tamori A et al (2021) Association of serum autotaxin levels with liver fibrosis in patients pretreatment and posttreatment with chronic hepatitis C. J Gastroenterol Hepatol 36:217–224. https://doi.org/10.1111/jgh.15114CrossRefPubMed

24.

Jansen S, Andries M, Vekemans K et al (2009) Rapid clearance of the circulating metastatic factor autotaxin by the scavenger receptors of liver sinusoidal endothelial cells. Cancer Lett 284:216–221. https://doi.org/10.1016/j.canlet.2009.04.029CrossRefPubMed

25.

Corbacioglu S, Greil J, Peters C et al (2004) Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transpl 33:189–195. https://doi.org/10.1038/sj.bmt.1704329CrossRef

26.

Bacigalupo A, Ballen K, Rizzo D et al (2009) Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl 15:1628–1633. https://doi.org/10.1016/j.bbmt.2009.07.004CrossRef

27.

Giralt S, Ballen K, Rizzo D et al (2009) Reduced-intensity conditioning Regimen Workshop: defining the dose spectrum. Report of a Workshop convened by the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transpl 15:367–369. https://doi.org/10.1016/j.bbmt.2008.12.497CrossRef

28.

Armand P, Kim HT, Logan BR et al (2014) Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood 123:3664–3671. https://doi.org/10.1182/blood-2014-01-552984CrossRefPubMedPubMedCentral

29.

Sorror ML, Maris MB, Storb R et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106:2912–2919. https://doi.org/10.1182/blood-2005-05-2004CrossRefPubMedPubMedCentral

30.

Braet F, Wisse E (2002) Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp Hepatol 1:1. https://doi.org/10.1186/1476-5926-1-1CrossRefPubMedPubMedCentral

31.

Carreras E (2015) How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation. Brit J Haematol 168:481–491. https://doi.org/10.1111/bjh.13215CrossRef

32.

Corbacioglu S, Cesaro S, Faraci M et al (2012) Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet 379:1301–1309. https://doi.org/10.1016/s0140-6736(11)61938-7CrossRefPubMed

33.

Dignan FL, Wynn RF, Hadzic N et al (2013) BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Brit J Haematol 163:444–457. https://doi.org/10.1111/bjh.12558CrossRef

34.

Chalandon Y, Mamez A-C, Giannotti F et al (2022) Defibrotide shows efficacy in the Prevention of Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: a retrospective study. Transpl Cell Ther 28. https://doi.org/10.1016/j.jtct.2022.08.003. :765.e1-765.e9

35.

Corbacioglu S, Topaloglu O, Aggarwal S (2022) A systematic review and Meta-analysis of studies of Defibrotide Prophylaxis for Veno-Occlusive Disease/Sinusoidal obstruction syndrome. Clin Drug Invest 42:465–476. https://doi.org/10.1007/s40261-022-01140-yCrossRef

36.

Nakai Y, Ikeda H, Nakamura K et al (2011) Specific increase in serum autotaxin activity in patients with pancreatic cancer. Clin Biochem 44:576–581. https://doi.org/10.1016/j.clinbiochem.2011.03.128CrossRefPubMed

37.

Masuda A, Nakamura K, Izutsu K et al (2008) Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma. Br J Haematol 143:60–70. https://doi.org/10.1111/j.1365-2141.2008.07325.xCrossRefPubMed

38.

Masuda A, Fujii T, Iwasawa Y et al (2011) Serum autotaxin measurements in pregnant women: application for the differentiation of normal pregnancy and pregnancy-induced hypertension. Clin Chim Acta 412:1944–1950. https://doi.org/10.1016/j.cca.2011.06.039CrossRefPubMed

39.

Nakanaga K, Hama K, Aoki J (2010) Autotaxin—an LPA producing enzyme with diverse functions. J Biochem 148:13–24. https://doi.org/10.1093/jb/mvq052CrossRefPubMed

40.

Ikeda H, Kobayashi M, Kumada H et al (2018) Performance of autotaxin as a serum marker of liver fibrosis. Ann Clin Biochem 55:469–477CrossRefPubMed

41.

Benesch MGK, Tang X, Dewald J et al (2015) Tumor-induced inflammation in mammary adipose tissue stimulates a vicious cycle of autotaxin expression and breast cancer progression. Faseb J 29:3990–4000. https://doi.org/10.1096/fj.15-274480CrossRefPubMed

42.

Sumida H, Nakamura K, Yanagida K et al (2013) Decrease in circulating autotaxin by oral administration of prednisolone. Clin Chim Acta 415:74–80. https://doi.org/10.1016/j.cca.2012.10.003CrossRefPubMed

43.

Mohty M, Malard F, Alaskar AS et al (2023) Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a refined classification from the European society for blood and marrow transplantation (EBMT). Bone Marrow Transpl 58:749–754. https://doi.org/10.1038/s41409-023-01992-8CrossRef

Title: Autotaxin is a potential predictive marker for the development of veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation
Authors: Kazuya Takemura
Mika Nakamae
Hiroshi Okamura
Kazuki Sakatoku
Kentaro Ido
Yosuke Makuuchi
Masatomo Kuno
Teruhito Takakuwa
Asao Hirose
Mitsutaka Nishimoto
Yasuhiro Nakashima
Hideo Koh
Koji Igarashi
Hiroshi Kubota
Masayuki Hino
Hirohisa Nakamae
Publication date: 18-03-2024
Publisher: Springer Berlin Heidelberg
Keyword: Biomarkers
Published in: Annals of Hematology / Issue 5/2024
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-024-05685-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2024

Is eryptosis druggable?

Correction to: Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patientreported outcomes from the CARDINAL study

Progression of myeloproliferative neoplasm with BCR::JAK2 fusion to acute leukemia of ambiguous lineage

Spanish registry of hemoglobinopathies and rare anemias (REHem-AR): demographics, complications, and management of patients with β-thalassemia

Impact of BK polyomavirus viremia on the outcomes of allogeneic hematopoietic stem cell transplantation

Allogeneic stem cell transplantation and CAR-T in B-cell Non-Hodgkin Lymphoma: a two-center experience and review of the literature

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials